MMP16

Summary

MMP16 (matrix metallopeptidase 16, HGNC:7162) is a protein-coding gene on chromosome 8q21.3, encoding Matrix metalloproteinase-16 (P51512). Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin.

Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP’s are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The encoded protein activates MMP2 by cleavage. This gene was once referred to as MT-MMP2, but was renamed as MT-MMP3 or MMP16.

Source: NCBI Gene 4325 — RefSeq curated summary.

At a glance

• GWAS associations: 29
• Clinical variants (ClinVar): 65 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005941

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7162
Approved symbol	MMP16
Name	matrix metallopeptidase 16
Location	8q21.3
Locus type	gene with protein product
Status	Approved
Aliases	MT3-MMP, DKFZp761D112
Ensembl gene	ENSG00000156103
Ensembl biotype	protein_coding
OMIM	602262
Entrez	4325

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000286614, ENST00000520568, ENST00000522726, ENST00000544227

RefSeq mRNA: 1 — MANE Select: NM_005941 NM_005941

CCDS: CCDS6246

Canonical transcript exons

ENST00000286614 — 10 exons

Exon	Start	End
ENSE00001088402	88046669	88046784
ENSE00001088408	88056128	88056278
ENSE00001260017	88032011	88041795
ENSE00001399203	88327075	88327483
ENSE00003486805	88186476	88186598
ENSE00003495602	88197158	88197306
ENSE00003555699	88118700	88118861
ENSE00003607975	88116507	88116718
ENSE00003624552	88167669	88167973
ENSE00003694472	88074605	88074743

Expression profiles

Bgee: expression breadth ubiquitous, 206 present calls, max score 93.48.

FANTOM5 (CAGE): breadth broad, TPM avg 3.2630 / max 65.6523, expressed in 881 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
93844	1.1805	482
93843	0.9571	463
93842	0.5846	315
93841	0.3298	173
93845	0.2110	101

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	93.48	gold quality
tibia	UBERON:0000979	92.70	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.61	gold quality
cartilage tissue	UBERON:0002418	90.34	gold quality
postcentral gyrus	UBERON:0002581	89.04	gold quality
middle temporal gyrus	UBERON:0002771	88.20	gold quality
parietal lobe	UBERON:0001872	88.13	gold quality
entorhinal cortex	UBERON:0002728	86.86	gold quality
cortical plate	UBERON:0005343	86.81	gold quality
superior frontal gyrus	UBERON:0002661	86.76	gold quality
stromal cell of endometrium	CL:0002255	86.19	gold quality
ventricular zone	UBERON:0003053	82.55	gold quality
primary visual cortex	UBERON:0002436	82.17	gold quality
occipital lobe	UBERON:0002021	82.11	gold quality
cerebellar vermis	UBERON:0004720	81.98	gold quality
ganglionic eminence	UBERON:0004023	81.46	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.41	gold quality
mammary duct	UBERON:0001765	80.75	gold quality
corpus callosum	UBERON:0002336	80.72	gold quality
substantia nigra pars reticulata	UBERON:0001966	79.22	gold quality
medial globus pallidus	UBERON:0002477	78.94	gold quality
substantia nigra pars compacta	UBERON:0001965	78.83	gold quality
buccal mucosa cell	CL:0002336	78.49	gold quality
epithelium of mammary gland	UBERON:0003244	78.24	gold quality
skin of hip	UBERON:0001554	77.67	gold quality
globus pallidus	UBERON:0001875	77.63	gold quality
superior vestibular nucleus	UBERON:0007227	77.19	gold quality
temporal lobe	UBERON:0001871	77.13	gold quality
adrenal tissue	UBERON:0018303	76.97	gold quality
subthalamic nucleus	UBERON:0001906	76.28	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	2311.31
E-HCAD-35	yes	91.02
E-HCAD-25	yes	27.90
E-GEOD-84465	yes	25.55
E-ENAD-27	yes	8.15
E-ANND-3	yes	6.08
E-GEOD-93593	yes	5.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

290 targeting MMP16, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817

Literature-anchored findings (GeneRIF, showing 35)

• down-regulation of most MT-MMPs is typical for prostate carcinoma; seems to occur mainly in epithelial cells (PMID:12661033)
• Results report the structure of the catalytic domain (cd) of the membrane-type matrix metalloproteinase MT3-MMP/MMP-16 in complex with the hydroxamic acid inhibitor batimastat. (PMID:14741217)
• MT3-MMP is not only important in matrix degradation but also may affect the function of focal adhesions through FAK cleavage. (PMID:15044209)
• Type-3 metalloproteinases, are identified as the triggering agents that independently confer cancer cells with the ability to proteolytically efface the BM scaffolding, initiate the assembly of invasive pseudopodia, and propagate transmigration. (PMID:16983145)
• Chondroitin-4-sulfate, which is expressed on tumour cell surface, can function to bind to pro-MMP-2 and facilitate its activation by MT3-MMP-expressing tumour cells to enhance invasion and metastasis (PMID:17217338)
• We have demonstrated the expression of MT3-MMP in hepatocellular carcinoma tissues (HCC) and that the expression in HCC significantly correlates with capsular invasion. (PMID:17419254)
• MMP16 polymorphisms appear to influence not only the pulmonary expression and function of MMP16 but also the risk of bronchopulmonary dysplasia (PMID:18784838)
• miR-146b is involved in glioma cell migration and invasion by targeting MMP16; implicating miR-146b as a metastasis-inhibiting miRNA in glioma (PMID:19265686)
• Matrix metalloproteinase 16 (MMP16) was a downstream target of miR-146b-5p. (PMID:21823013)
• MT3-MMP is a matrix-dependent modifier of the invasive tumor cell functions during melanoma progression (PMID:22164270)
• Data show that MMP16 is regulated by miR-146a in spontaneously differentiated Caco-2 cells. (PMID:22348245)
• The overexpression of miR-146b-5p in glioblastoma cell lines led to MMP16 mRNA silencing, MMP2 inactivation, and the inhibition of tumour cell migration and invasion. (PMID:23796692)
• E2F1 acts as a transcriptional activator for MMPs and directly enhances MMP transcription by binding to E2F1 binding sequences in the promoter, or indirectly activates MMPs (MMP-9 and MMP-16)through enhanced Sp1 and NF-kappa B (PMID:24755270)
• the results support a role for MMP16 in promoting invasive properties of the meningioma tumours (PMID:24989599)
• Expression of MMP-16 in HTB9 and T24 cells increases following transforming growth factorbeta1 treatment. (PMID:25017509)
• MMP16 is a putative indicator of adverse melanoma prognosis. (PMID:25808867)
• These results demonstrate that the MT3-MMP promoter is frequently hypermethylated in colorectal cancer and that downregulation of MT3-MMP may be important for cell migration in colorectal cancer. (PMID:26002729)
• results suggest that miR-145 functions as a tumor metastasis suppressor gene by down-regulating MMP16 and may be a potential target in osteosarcoma treatment (PMID:26605780)
• more severe intervertebral disc degeneration is correlated with higher matrix metallopeptidase 16 (PMID:27227700)
• the present findings indicate that MT3-MMP is down-regulated in ESCC, which correlates to lymph node metastasis and poor survival of patients with this disease. (PMID:27292876)
• MMP16 was highly expressed and correlated with poor prognosis in gastric cancer patients by promoting proliferation and invasion of gastric cancer cells (PMID:27340864)
• Findings suggest that these MMP16 rs10090371, ADAMTS3 rs788935, TLL2 rs10882807 and MMP9 rs3918251 may be promising prognostic biomarkers for cutaneous melanoma specific survival (CMSS). (PMID:28796414)
• Overexpression of MMP2 and MMP16 in endometrial cancerous tissues corresponded to down-regulation of miR-377, miR-382 and miR-410, while decreased expression of TIMP2 was associated with miR-200b up-regulation. (PMID:28871006)
• HOXA11-AS could promote renal cancer cells growth and invasion by modulating miR-146b-5p-MMP16 axis. (PMID:29953617)
• A protective polymorphism in MMP16, improved blood gas levels, and chronic obstructive pulmonary diseases: Family and two population-based studies. (PMID:32196811)
• LINC01121 induced intervertebral disc degeneration via modulating miR-150-5p/MMP16 axis. (PMID:32436632)
• Role of lncRNA NEAT1 mediated by YY1 in the development of diabetic cataract via targeting the microRNA-205-3p/MMP16 axis. (PMID:32572898)
• Knockdown of MMP16 inhibits cell proliferation and invasion in chordoma in vitro. (PMID:33210500)
• Association between MMP16 rs60298754 and clinical phenotypes of Parkinson’s disease in southern Chinese. (PMID:33241532)
• microRNA-4429-5p suppresses the malignant development of colon cancer by targeting matrix metalloproteinase 16. (PMID:34448115)
• LncRNA NEAT1 regulates MMP-16 by targeting miR-200a/b to aggravate inflammation in asthma. (PMID:34448644)
• Circular RNA hsa_circ_0002360 promotes non-small cell lung cancer progression through upregulating matrix metalloproteinase 16 and sponging multiple micorRNAs. (PMID:34747300)
• Changes in the expression of membrane type-matrix metalloproteinases genes (MMP14, MMP15, MMP16, MMP24) during treatment and their potential impact on the survival of patients with non-small cell lung cancer (NSCLC). (PMID:35062057)
• MMP16 as NSCL +/- P Susceptible Gene in Western Han Chinese. (PMID:36120833)
• M1 macrophage-derived exosomes containing miR-150 inhibit glioma progression by targeting MMP16. (PMID:37244635)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	mmp16b	ENSDARG00000058876
danio_rerio		ENSDARG00000116438
mus_musculus	Mmp16	ENSMUSG00000028226
rattus_norvegicus	Mmp16	ENSRNOG00000005708
caenorhabditis_elegans		WBGENE00010524
caenorhabditis_elegans		WBGENE00012185
caenorhabditis_elegans		WBGENE00012364
caenorhabditis_elegans		WBGENE00016283
caenorhabditis_elegans		WBGENE00194737

Paralogs (23): MMP25 (ENSG00000008516), MMP2 (ENSG00000087245), MMP11 (ENSG00000099953), MMP9 (ENSG00000100985), MMP15 (ENSG00000102996), HPX (ENSG00000110169), MMP8 (ENSG00000118113), MMP19 (ENSG00000123342), MMP24 (ENSG00000125966), MMP7 (ENSG00000137673), MMP20 (ENSG00000137674), MMP27 (ENSG00000137675), MMP13 (ENSG00000137745), MMP3 (ENSG00000149968), MMP21 (ENSG00000154485), MMP14 (ENSG00000157227), MMP10 (ENSG00000166670), MMP26 (ENSG00000167346), MMP23B (ENSG00000189409), MMP1 (ENSG00000196611), MMP17 (ENSG00000198598), MMP12 (ENSG00000262406), MMP28 (ENSG00000271447)

Protein

Protein identifiers

Matrix metalloproteinase-16 — P51512 (reviewed: P51512)

Alternative names: MMP-X2, Membrane-type matrix metalloproteinase 3, Membrane-type-3 matrix metalloproteinase

All UniProt accessions (2): P51512, E5RJA7

UniProt curated annotations — full annotation on UniProt →

Function. Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells.

Subunit / interactions. Interacts with CSPG4 through CSPG4 chondroitin sulfate glycosaminoglycan.

Subcellular location. Cell membrane Secreted. Extracellular space. Extracellular matrix. Cell surface.

Tissue specificity. Expressed in heart, brain, placenta, ovary and small intestine. Isoform Short is found in the ovary.

Post-translational modifications. The precursor is cleaved by a furin endopeptidase.

Activity regulation. TIMP-2 shows little inhibitory activity compared to TIMP-1. TIMP-1 seems to have less binding affinity than TIMP-2 for the short isoform.

Cofactor. Binds 2 zinc ions per subunit.

Domain organisation. The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.

Similarity. Belongs to the peptidase M10A family.

Isoforms (2)

UniProt ID	Names	Canonical?
P51512-1	Long	yes
P51512-2	Short, SM3

RefSeq proteins (1): NP_005932* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000585	Hemopexin-like_dom	Domain
IPR001818	Pept_M10_metallopeptidase	Domain
IPR002477	Peptidoglycan-bd-like	Domain
IPR006026	Peptidase_Metallo	Domain
IPR018486	Hemopexin_CS	Conserved_site
IPR018487	Hemopexin-like_repeat	Repeat
IPR021158	Pept_M10A_Zn_BS	Binding_site
IPR021190	Pept_M10A	Family
IPR021805	Pept_M10A_metallopeptidase_C	Domain
IPR024079	MetalloPept_cat_dom_sf	Homologous_superfamily
IPR033739	M10A_MMP	Domain
IPR036365	PGBD-like_sf	Homologous_superfamily
IPR036375	Hemopexin-like_dom_sf	Homologous_superfamily

Pfam: PF00045, PF00413, PF01471, PF11857

UniProt features (53 total): binding site 18, strand 11, repeat 4, helix 3, topological domain 2, splice variant 2, turn 2, signal peptide 1, propeptide 1, region of interest 1, short sequence motif 1, compositionally biased region 1, active site 1, chain 1, glycosylation site 1, disulfide bond 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1RM8	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P51512-F1	77.06	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 247

Ligand- & substrate-binding residues (18): 101 (in inhibited form); 183; 193; 195; 200; 201; 203; 205; 208; 215; 217; 219 …

Disulfide bonds (1): 343–532

Glycosylation sites (1): 83

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-1592389	Activation of Matrix Metalloproteinases
R-HSA-9839383	TGFBR3 PTM regulation
R-HSA-1474228	Degradation of the extracellular matrix
R-HSA-1474244	Extracellular matrix organization
R-HSA-162582	Signal Transduction
R-HSA-9006936	Signaling by TGFB family members
R-HSA-9839373	Signaling by TGFBR3

MSigDB gene sets: 251 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, AAGCAAT_MIR137, TAATAAT_MIR126, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_EMBRYONIC_SKELETAL_SYSTEM_DEVELOPMENT, AREB6_03, GOBP_EMBRYONIC_SKELETAL_SYSTEM_MORPHOGENESIS, GOZGIT_ESR1_TARGETS_DN, GOCC_CELL_SURFACE, CERVERA_SDHB_TARGETS_1_DN, LIEN_BREAST_CARCINOMA_METAPLASTIC, GOBP_REPLACEMENT_OSSIFICATION, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_ANIMAL_ORGAN_MORPHOGENESIS

GO Biological Process (11): skeletal system development (GO:0001501), endochondral ossification (GO:0001958), proteolysis (GO:0006508), protein processing (GO:0016485), extracellular matrix organization (GO:0030198), collagen catabolic process (GO:0030574), chondrocyte proliferation (GO:0035988), embryonic cranial skeleton morphogenesis (GO:0048701), craniofacial suture morphogenesis (GO:0097094), ossification (GO:0001503), bone development (GO:0060348)

GO Molecular Function (8): metalloendopeptidase activity (GO:0004222), enzyme activator activity (GO:0008047), zinc ion binding (GO:0008270), metalloaminopeptidase activity (GO:0070006), peptidase activity (GO:0008233), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (7): obsolete extracellular space (GO:0005615), Golgi lumen (GO:0005796), plasma membrane (GO:0005886), cell surface (GO:0009986), extracellular matrix (GO:0031012), extracellular region (GO:0005576), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Degradation of the extracellular matrix	1
Signaling by TGFBR3	1
Extracellular matrix organization	1
Signal Transduction	1
Signaling by TGFB family members	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cranial skeletal system development	2
catalytic activity	2
system development	1
replacement ossification	1
endochondral bone morphogenesis	1
protein metabolic process	1
proteolysis	1
protein maturation	1
extracellular structure organization	1
external encapsulating structure organization	1
catabolic process	1
collagen metabolic process	1
cell population proliferation	1
embryonic skeletal system morphogenesis	1
anatomical structure morphogenesis	1
bone morphogenesis	1
multicellular organismal process	1
skeletal system development	1
animal organ development	1
endopeptidase activity	1
metallopeptidase activity	1
enzyme regulator activity	1
molecular function activator activity	1
transition metal ion binding	1
aminopeptidase activity	1
metalloexopeptidase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
cation binding	1
Golgi apparatus	1
intracellular organelle lumen	1
membrane	1
cell periphery	1
external encapsulating structure	1

Protein interactions and networks

STRING

1124 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MMP16	SPOCK3	Q9BQ16	843
MMP16	SPOCK2	Q92563	817
MMP16	SPOCK1	Q08629	797
MMP16	TIMP2	P16035	768
MMP16	TIMP1	P01033	740
MMP16	TIMP3	P35625	611
MMP16	TIMP4	Q99727	593
MMP16	CD44	P16070	555
MMP16	PLG	P00747	553
MMP16	COL15A1	P39059	521
MMP16	NT5C2	P49902	507
MMP16	COL12A1	Q99715	504
MMP16	PLAT	P00750	495
MMP16	CSPG4	Q6UVK1	490
MMP16	VRK2	Q86Y07	477

IntAct

2 interactions, top by confidence:

A	B	Type	Score
MMP16	Gorasp2	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (15): MMP16 (Affinity Capture-RNA), MMP16 (Affinity Capture-MS), MMP17 (Negative Genetic), MMP24 (Negative Genetic), MMP16 (Negative Genetic), MMP16 (Negative Genetic), MMP16 (Negative Genetic), MMP16 (Negative Genetic), MMP16 (Negative Genetic), MMP16 (Negative Genetic), MMP20 (Negative Genetic), MMP27 (Negative Genetic), MMP7 (Negative Genetic), MMP8 (Negative Genetic), MMP16 (Affinity Capture-RNA)

ESM2 similar proteins: A0A044RE18, B4F6N6, B5DF27, E1C3U7, F1QQC3, G5ECN9, O17798, O35548, O64481, P09231, P09958, P13134, P16519, P21661, P23188, P23377, P28840, P28841, P29119, P29120, P29122, P29145, P29146, P30432, P41413, P51512, P51559, P58022, P63239, P63240, P91863, Q03333, Q04592, Q08B63, Q09175, Q28193, Q5REC2, Q63415, Q8QGP3, Q8SQJ3

Diamond homologs: D0EM77, G5EBU3, O04529, O13065, O18733, O18767, O18927, O23507, O35548, O44836, O54732, O55123, O55761, O60882, O62806, O70138, O75900, O77656, O88272, O88676, O88766, O93470, P03956, P03957, P07152, P08253, P08254, P09237, P09238, P13943, P14780, P21692, P22757, P22894, P23097, P24347, P28053, P28862, P28863, P29136

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
MMP16	up-regulates	ECM_disassembly
MMP16	down-regulates	ECM

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	1
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

3662 predictions. Top by Δscore:

Variant	Effect	Δscore
8:88035975:A:C	acceptor_gain	1.0000
8:88046663:GCATA:G	donor_loss	1.0000
8:88046664:CATAC:C	donor_loss	1.0000
8:88046665:ATAC:A	donor_loss	1.0000
8:88046666:TACCA:T	donor_loss	1.0000
8:88046667:ACCAT:A	donor_loss	1.0000
8:88046692:C:CA	donor_gain	1.0000
8:88046782:TAT:T	acceptor_gain	1.0000
8:88056123:CTGA:C	donor_loss	1.0000
8:88056124:TGA:T	donor_loss	1.0000
8:88056125:GA:G	donor_loss	1.0000
8:88056126:A:AG	donor_loss	1.0000
8:88056127:C:T	donor_loss	1.0000
8:88056127:CCTGT:C	donor_gain	1.0000
8:88056277:ACC:A	acceptor_loss	1.0000
8:88056283:A:C	acceptor_gain	1.0000
8:88118697:TA:T	donor_loss	1.0000
8:88118698:A:AC	donor_gain	1.0000
8:88118699:C:CA	donor_loss	1.0000
8:88118699:C:CC	donor_gain	1.0000
8:88141048:A:C	donor_gain	1.0000
8:88141086:T:A	donor_gain	1.0000
8:88167663:ACTT:A	donor_loss	1.0000
8:88167666:TACC:T	donor_loss	1.0000
8:88167667:A:AC	donor_gain	1.0000
8:88167667:AC:A	donor_gain	1.0000
8:88167667:ACCAT:A	donor_gain	1.0000
8:88167668:C:CG	donor_gain	1.0000
8:88167668:CC:C	donor_gain	1.0000
8:88167668:CCA:C	donor_gain	1.0000

AlphaMissense

4024 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:88046718:C:A	W480C	1.000
8:88046718:C:G	W480C	1.000
8:88046720:A:G	W480R	1.000
8:88046720:A:T	W480R	1.000
8:88074674:A:G	W385R	1.000
8:88074674:A:T	W385R	1.000
8:88074727:C:G	R367P	1.000
8:88074731:A:G	W366R	1.000
8:88074731:A:T	W366R	1.000
8:88116514:A:T	V359D	1.000
8:88116562:C:G	C343S	1.000
8:88116563:A:T	C343S	1.000
8:88118726:T:C	D282G	1.000
8:88118727:C:G	D282H	1.000
8:88118738:A:T	L278Q	1.000
8:88118779:C:A	M264I	1.000
8:88118779:C:G	M264I	1.000
8:88118779:C:T	M264I	1.000
8:88118780:A:C	M264R	1.000
8:88118780:A:G	M264T	1.000
8:88118786:G:T	A262D	1.000
8:88118787:C:G	A262P	1.000
8:88118801:G:A	S257F	1.000
8:88118802:A:G	S257P	1.000
8:88118803:A:C	H256Q	1.000
8:88118803:A:T	H256Q	1.000
8:88118804:T:C	H256R	1.000
8:88118805:G:C	H256D	1.000
8:88118810:A:G	L254S	1.000
8:88118813:C:T	G253E	1.000

dbSNP variants (sampled 300 via entrez): RS1000000891 (8:88181277 T>C), RS1000007563 (8:88049436 T>C), RS1000018420 (8:88051498 T>A,C), RS1000023598 (8:88185518 A>G), RS1000039588 (8:88309064 T>C), RS1000039823 (8:88265720 G>T), RS1000042357 (8:88249992 A>G,T), RS1000048837 (8:88244356 C>T), RS1000051779 (8:88268776 A>C), RS1000056161 (8:88185066 T>A), RS1000065474 (8:88271622 T>A), RS1000080170 (8:88100563 G>A), RS1000083333 (8:88166315 G>C), RS1000089671 (8:88296197 G>A), RS1000097337 (8:88224024 T>C)

Disease associations

OMIM: gene MIM:602262 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

29 associations (top):

Study	Trait	p-value
GCST001242_12	Schizophrenia	2.000000e-07
GCST001440_1	Body mass index and cholesterol (psychopharmacological treatment)	6.000000e-08
GCST001565_11	Schizophrenia	6.000000e-08
GCST001877_37	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	3.000000e-08
GCST002078_1	Migraine without aura	1.000000e-08
GCST002149_21	Schizophrenia	3.000000e-08
GCST002539_74	Schizophrenia	1.000000e-08
GCST003073_5	Cerebral amyloid deposition (PET imaging)	7.000000e-07
GCST004049_30	Cough in response to angiotensin-converting enzyme inhibitor drugs	3.000000e-06
GCST004521_109	Autism spectrum disorder or schizophrenia	2.000000e-08
GCST004521_288	Autism spectrum disorder or schizophrenia	5.000000e-08
GCST004946_102	Schizophrenia	1.000000e-08
GCST006803_80	Schizophrenia	7.000000e-09
GCST006941_30	Irritable mood	6.000000e-09
GCST006979_467	Heel bone mineral density	1.000000e-16
GCST007201_100	Schizophrenia	3.000000e-08
GCST007201_311	Schizophrenia	7.000000e-07
GCST008018_5	Sweet taste perception in obesity with metabolic syndrome	8.000000e-06
GCST008103_110	Bipolar disorder	4.000000e-06
GCST010002_308	Refractive error	1.000000e-10
GCST90000025_367	Appendicular lean mass	4.000000e-26
GCST90020024_179	A body shape index	1.000000e-08
GCST90020024_181	A body shape index	7.000000e-12
GCST90020025_1022	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST90020025_1023	Waist-to-hip ratio adjusted for BMI	1.000000e-11
GCST90020027_1379	Waist-hip index	6.000000e-09
GCST90020027_1380	Waist-hip index	6.000000e-12
GCST90020029_87	Waist circumference adjusted for body mass index	2.000000e-08
GCST90020029_89	Waist circumference adjusted for body mass index	2.000000e-11

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0007707	cerebral amyloid deposition measurement
EFO:0005325	response to angiotensin-converting enzyme inhibitor
EFO:0009594	irritability measurement
EFO:0009270	heel bone mineral density
EFO:0004980	appendicular lean mass
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2200 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 41,512 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL279785	MARIMASTAT	3	29,447
CHEMBL19611	ILOMASTAT	2	12,065

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M10: Matrix metallopeptidase

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
ilomastat	Inhibition	8.1	pIC50
SL422	Inhibition	7.46	pKi

ChEMBL bioactivities

52 potent at pChembl≥5 of 57 total, top 49 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.51	IC50	0.31	nM	CHEMBL471537
9.00	IC50	1	nM	CHEMBL234530
8.81	IC50	1.56	nM	CHEMBL515980
8.17	IC50	6.8	nM	CGS-27023A
8.10	IC50	8	nM	ILOMASTAT
7.94	IC50	11.4	nM	CHEMBL472899
7.80	IC50	16	nM	CHEMBL148214
7.68	IC50	21	nM	CHEMBL147882
7.66	IC50	22	nM	CHEMBL358539
7.50	IC50	32	nM	CHEMBL573715
7.46	Ki	35	nM	CHEMBL88520
7.46	IC50	35	nM	CHEMBL147881
7.41	IC50	39	nM	CHEMBL1939846
7.40	IC50	40	nM	CHEMBL148171
7.36	IC50	44	nM	CHEMBL234529
7.29	IC50	51	nM	CHEMBL561963
7.29	IC50	51	nM	CHEMBL179288
7.25	IC50	56	nM	CHEMBL146718
6.97	Ki	107	nM	CHEMBL91636
6.89	IC50	130	nM	CHEMBL573714
6.89	IC50	130	nM	CHEMBL584365
6.82	IC50	150	nM	CHEMBL572780
6.75	IC50	177	nM	CHEMBL147489
6.74	IC50	184	nM	CHEMBL146289
6.73	IC50	186	nM	CHEMBL234735
6.70	IC50	202	nM	CHEMBL148406
6.66	IC50	220	nM	CHEMBL574370
6.33	IC50	470	nM	CHEMBL574605
6.14	IC50	730	nM	CHEMBL573936
6.05	IC50	900	nM	CHEMBL181244
6.03	IC50	940	nM	BAY-7598
6.00	IC50	996	nM	CHEMBL515083
5.96	IC50	1100	nM	CHEMBL584147
5.96	IC50	1100	nM	CHEMBL1939844
5.92	IC50	1200	nM	CHEMBL573934
5.89	IC50	1300	nM	CHEMBL575896
5.80	Ki	1599	nM	CHEMBL148169
5.78	IC50	1677	nM	CHEMBL356124
5.74	IC50	1839	nM	CHEMBL424130
5.70	Ki	2000	nM	CHEMBL325163
5.66	IC50	2200	nM	CHEMBL1939845
5.37	IC50	4300	nM	CHEMBL573935
5.33	IC50	4633	nM	CHEMBL147604
5.30	IC50	5000	nM	CHEMBL550548
5.29	IC50	5100	nM	CHEMBL574589
5.22	IC50	6000	nM	CHEMBL584122
5.20	IC50	6300	nM	CHEMBL579068
5.19	IC50	6500	nM	CHEMBL579067
5.00	IC50	1e+04	nM	MARIMASTAT

PubChem BioAssay actives

51 with measured affinity, of 82 total; 48 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R)-N-hydroxy-3-methyl-2-[[2-oxo-2-[2-(4-sulfamoylphenyl)ethylamino]ethyl]-(4-phenoxyphenyl)sulfonylamino]butanamide	413962: Inhibition of MMP16	ic50	0.0003	uM
2-[[2-(hydroxyamino)-2-oxoethyl]-(4-phenoxyphenyl)sulfonylamino]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	413962: Inhibition of MMP16	ic50	0.0010	uM
2-[[(2R)-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(4-phenoxyphenyl)sulfonylamino]acetic acid	413962: Inhibition of MMP16	ic50	0.0016	uM
(2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride	413962: Inhibition of MMP16	ic50	0.0068	uM
(2R)-N’-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.0080	uM
2-[[2-(hydroxyamino)-2-oxoethyl]-(4-phenoxyphenyl)sulfonylamino]acetic acid	413962: Inhibition of MMP16	ic50	0.0114	uM
N,6-dihydroxy-7-methoxy-2-(4-methoxyphenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.0160	uM
N,6-dihydroxy-2-(4-methylphenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.0210	uM
N-hydroxy-2-(4-methoxyphenyl)sulfonyl-6-phenylmethoxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.0220	uM
N-hydroxy-2-[2-[4-(4-methoxyphenoxy)phenyl]sulfonylphenyl]acetamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.0320	uM
(6S,7R,10S)-6-N-hydroxy-10-N-[2-(methylamino)-2-oxoethyl]-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide	109573: Inhibition of matrix metalloprotease-16	ki	0.0350	uM
2-(benzenesulfonyl)-N-hydroxy-6-phenylmethoxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.0350	uM
(3R)-1-hydroxy-4-(4-phenoxyphenyl)sulfonyl-3-propan-2-ylpiperazine-2,6-dione	641681: Inhibition of human recombinant MMP16 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate preincubated for 4 hrs measured every 15 secs for 20 mins by fluorescence analysis	ic50	0.0390	uM
2-(benzenesulfonyl)-N,6-dihydroxy-7-methoxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.0400	uM
2-[[2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonylamino]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	413962: Inhibition of MMP16	ic50	0.0440	uM
(2R)-N-hydroxy-3-methyl-2-[(4-phenylphenyl)sulfonyl-propan-2-yloxyamino]butanamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.0510	uM
N-hydroxy-3-methyl-2-[propan-2-yloxy-[4-(4-propan-2-ylphenyl)phenyl]sulfonylamino]butanamide	419744: Inhibition of human recombinant MMP16	ic50	0.0510	uM
N-hydroxy-2-(4-methylphenyl)sulfonyl-6-phenylmethoxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.0560	uM
(8S,11R,12S)-12-N-hydroxy-11-(2-methylpropyl)-8-N-(2-morpholin-4-yl-2-oxoethyl)-2,10-dioxo-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide	109573: Inhibition of matrix metalloprotease-16	ki	0.1070	uM
N-hydroxy-2-[2-(4-methoxyphenyl)sulfonylphenyl]acetamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.1300	uM
N-hydroxy-2-[2-[4-(4-methoxyphenyl)phenyl]sulfonylphenyl]acetamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.1300	uM
N-hydroxy-2-[2-[4-(4-methoxyphenyl)phenyl]sulfonylphenyl]propanamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.1500	uM
N,6-dihydroxy-2-(4-nitrophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.1770	uM
2-(benzenesulfonyl)-N,6-dihydroxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.1840	uM
2-[[2-(hydroxyamino)-2-oxoethyl]-(4-phenylphenyl)sulfonylamino]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	413962: Inhibition of MMP16	ic50	0.1860	uM
2-(4-aminophenyl)sulfonyl-N,6-dihydroxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	0.2020	uM
N-hydroxy-2-[2-(4-phenylphenyl)sulfonylphenyl]acetamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.2200	uM
N-hydroxy-2-[2-(4-phenylphenyl)sulfonylphenyl]propanamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.4700	uM
2-[2-[4-(4-methoxyphenyl)phenyl]sulfonylphenyl]acetic acid	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	0.7300	uM
N-hydroxy-2-[(4-phenylphenyl)sulfonyl-propan-2-yloxyamino]acetamide	419744: Inhibition of human recombinant MMP16	ic50	0.9000	uM
2-[[2-(hydroxyamino)-2-oxoethyl]-(4-methoxyphenyl)sulfonylamino]acetic acid	413962: Inhibition of MMP16	ic50	0.9960	uM
2-[2-[4-(4-methoxyphenyl)phenyl]sulfonylphenyl]propanoic acid	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	1.1000	uM
(3R)-1-hydroxy-4-(4-methoxyphenyl)sulfonyl-3-propan-2-ylpiperazine-2,6-dione	641681: Inhibition of human recombinant MMP16 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate preincubated for 4 hrs measured every 15 secs for 20 mins by fluorescence analysis	ic50	1.1000	uM
N-hydroxy-2-[4-(4-methoxyphenyl)phenyl]sulfonylbenzamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	1.2000	uM
N-hydroxy-2-(4-phenoxyphenyl)sulfonylbenzamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	1.3000	uM
(2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide	109572: Affinity for Matrix metalloprotease-16 (MMP-16)	ki	1.5990	uM
N,6-dihydroxy-2-(4-methoxyphenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	1.6770	uM
2-(2,5-dichlorophenyl)sulfonyl-N,6-dihydroxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	1.8390	uM
(8S,11R,12S)-12-N-hydroxy-8-N-(2-morpholin-4-yl-2-oxoethyl)-2,10-dioxo-11-[[4-[2-(trifluoromethyl)phenyl]phenyl]methyl]-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide	109574: Inhibition of matrix metalloprotease-16	ki	2.0000	uM
(3R)-1-hydroxy-4-(4-phenylphenyl)sulfonyl-3-propan-2-ylpiperazine-2,6-dione	641681: Inhibition of human recombinant MMP16 using Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate preincubated for 4 hrs measured every 15 secs for 20 mins by fluorescence analysis	ic50	2.2000	uM
2-[2-(4-phenylphenyl)sulfonylphenyl]acetic acid	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	4.3000	uM
2-(2,5-dichlorophenyl)sulfonyl-N-hydroxy-6-phenylmethoxy-3,4-dihydro-1H-isoquinoline-1-carboxamide	109575: Inhibition of matrix metalloprotease-16 (MMP-16)	ic50	4.6330	uM
(2R)-2-[[4-[4-[(4-chlorophenyl)methoxy]phenyl]phenyl]sulfonyl-propan-2-yloxyamino]-N-hydroxy-3-methylbutanamide	419744: Inhibition of human recombinant MMP16	ic50	5.0000	uM
N-hydroxy-2-(4-phenylphenyl)sulfonylbenzamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	5.1000	uM
N-hydroxy-2-[4-(4-methoxyphenoxy)phenyl]sulfonylbenzamide	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	6.0000	uM
2-[2-(4-phenylphenyl)sulfonylphenyl]propanoic acid	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	6.3000	uM
2-[2-[4-(4-methoxyphenoxy)phenyl]sulfonylphenyl]acetic acid	440428: Inhibition of human recombinant pro-MMP16 catalytic domain after 4 hrs by fluorimetry	ic50	6.5000	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(2-methylpropyl)butanediamide	1274673: Inhibition of MMP16 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay	ic50	10.0000	uM

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, increases expression	3
entinostat	decreases expression, affects cotreatment	2
Resveratrol	decreases expression, affects cotreatment	2
Vorinostat	decreases expression, increases expression	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Estradiol	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	decreases expression	2
aristolochic acid I	decreases expression	1
geldanamycin	increases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases methylation	1
afimoxifene	decreases expression, decreases reaction	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
potassium chromate(VI)	decreases expression	1
nickel sulfate	decreases expression	1
mercuric bromide	decreases expression	1
glycidamide	decreases expression	1
chromium hexavalent ion	decreases expression	1
CGS 27023A	affects activity	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	increases methylation	1
Calcitriol	decreases expression, affects cotreatment	1
Cisplatin	increases expression	1

ChEMBL screening assays

20 unique, capped per target: 20 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1005428	Binding	Inhibition of MMP16 up to 100 uM	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. — Bioorg Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SY62	HAP1 MMP16 (-) 1	Cancer cell line	Male
CVCL_SY63	HAP1 MMP16 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.